Vault-13

AJU IB Investment Co., Ltd.

Seoul, M5 · CIK 1710065 · 13F filing filed 2021-08-10

No investment adviser registration (Form ADV) found for this filer. It may be a parent company whose subsidiaries are the registered advisers, a bank or insurer, or a manager based outside the US.

$173.4m reported value -34.6% vs Q1 2021
11positions
100.0%in top 10
0 new 0 added 5 reduced 0 sold out vs Q1 2021

Holdings, Q2 2021

The small lines show how much was held over the last 4 quarters (adjusted for stock splits).

#SecurityTickerShares Value% of portfolioChangeShares change
1 APELLIS PHARMACEUTICALS INC COM APLS APLS 1,064,962 $67.3m38.81% 38.81% ReducedShares held: Q3 2020 —, Q4 2020 1.1m, Q1 2021 1.1m, Q2 2021 1.1m -50.0k -50,000 -4.5%
2 ATEA PHARMACEUTICALS INC COM AVIR AVIR 1,745,331 $37.5m21.62% 21.62% ReducedShares held: Q3 2020 —, Q4 2020 2.0m, Q1 2021 2.0m, Q2 2021 1.7m -304.0k -304,000 -14.8%
3 KYMERA THERAPEUTICS INC COM KYMR KYMR 639,059 $31.0m17.87% 17.87% UnchangedShares held: Q3 2020 —, Q4 2020 704.1k, Q1 2021 639.1k, Q2 2021 639.1k
4 SEER INC COM CL A SEER SEER 816,375 $26.8m15.43% 15.43% ReducedShares held: Q3 2020 —, Q4 2020 1.1m, Q1 2021 1.1m, Q2 2021 816.4k -250.0k -250,000 -23.4%
5 SUTRO BIOPHARMA INC COM COM 175,000 $3.3m1.88% 1.88% UnchangedShares held: Q3 2020 —, Q4 2020 175.0k, Q1 2021 175.0k, Q2 2021 175.0k
6 RAPT THERAPEUTICS INC COM COM 99,503 $3.2m1.82% 1.82% ReducedShares held: Q3 2020 —, Q4 2020 108.5k, Q1 2021 108.5k, Q2 2021 99.5k -9.0k -9,000 -8.3%
7 MOLECULAR TEMPLATES INC COM COM 204,809 $1.6m0.92% 0.92% UnchangedShares held: Q3 2020 —, Q4 2020 204.8k, Q1 2021 204.8k, Q2 2021 204.8k
8 CLEARSIDE BIOMEDICAL INC COM COM 293,555 $1.4m0.82% 0.82% ReducedShares held: Q3 2020 —, Q4 2020 793.6k, Q1 2021 793.6k, Q2 2021 293.6k -500.0k -500,000 -63.0%
9 KEZAR LIFE SCIENCES INC COM COM 128,916 $700.0k0.40% 0.40% UnchangedShares held: Q3 2020 —, Q4 2020 128.9k, Q1 2021 128.9k, Q2 2021 128.9k
10 AILERON THERAPEUTICS INC COM ALRN ALRN 517,558 $647.0k0.37% 0.37% UnchangedShares held: Q3 2020 —, Q4 2020 517.6k, Q1 2021 517.6k, Q2 2021 517.6k
11 BELLICUM PHARMACEUTICALS INC COM NEW BLCM BLCM 25,651 $85.0k0.05% 0.05% UnchangedShares held: Q3 2020 —, Q4 2020 25.7k, Q1 2021 25.7k, Q2 2021 25.7k